nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

05.12.2019 | Book Review

ATLAS OF PET-CT, A Quick Guide to Image Interpretation

Stefano Fanti, Mohsen Farsad, Luigi Mansi, Paolo Castellucci Second Edition, Springer, 2018 ISBN 978-3-662-57742-4

verfasst von: Ignasi Carrió

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Excerpt

The new edition of the Atlas of PET–CT by Stefano Fanti and coworkers is a nice, practically oriented, and well-illustrated compilation of PET–CT clinical cases that will be extremely helpful to nuclear medicine physicians, in particular those training in residency programs. …

Titel: ATLAS OF PET-CT, A Quick Guide to Image Interpretation
Stefano Fanti, Mohsen Farsad, Luigi Mansi, Paolo Castellucci Second Edition, Springer, 2018 ISBN 978-3-662-57742-4
verfasst von: Ignasi Carrió
Publikationsdatum: 05.12.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04618-8

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT

Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas

Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer